Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

79.52
+2.142.77%
Post-market: 79.520.00000.00%19:46 EDT
Volume:2.56M
Turnover:206.25M
Market Cap:3.88B
PE:-18.40
High:88.68
Open:81.30
Low:77.84
Close:77.38
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:2.86
T/O Rate:8.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-303.41
PE(LYR):-20.98

Loading ...

BRIEF-Celcuity - Offering $400 Million Convertible Senior Notes Due 2032 - SEC Filing

Reuters
·
Jun 03

Celcuity launches USD 400 million convertible senior notes offering due 2032

Reuters
·
Jun 03

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

GlobeNewswire
·
Jun 03

Celcuity - Offering $400 Mln Convertible Senior Notes Due 2032 - SEC Filing

THOMSON REUTERS
·
Jun 03

Celcuity price target lowered to $145 from $185 at H.C. Wainwright

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

TIPRANKS
·
Jun 03

U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty

Reuters
·
Jun 03

Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial

MT Newswires Live
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Celcuity (CELC)

TIPRANKS
·
Jun 03

Celcuity plunges after experimental breast cancer treatment data disappoints

Reuters
·
Jun 03

Movement Alert|Celcuity Falls 23.24% in Regular Trading, Phase III VIKTORIA-1 Data Triggers Sell-the-News Reaction

Market Focus
·
Jun 03

Celcuity falls -22.2%

TIPRANKS
·
Jun 03

Celcuity reports efficacy, safety data from PIK3CA mutant cohort of VIKTORIA-1

TIPRANKS
·
Jun 02

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Moderna (MRNA) and Celcuity (CELC)

TIPRANKS
·
Jun 02

Celcuity Shares Fall 20.7% Premarket After Co Reports Late-Stage Data for Breast Cancer Drug

THOMSON REUTERS
·
Jun 02

Celcuity - Announces Phase 3 VIKTORIA-1 Trial Results For PIK3CA MT Cohort - SEC Filing

Reuters
·
Jun 02

Celcuity says Phase 3 VIKTORIA-1 shows gedatolisib combo halves progression or death risk vs alpelisib in PIK3CA-mutant breast cancer

Reuters
·
Jun 02

Celcuity - Gedatolisib-Triplet Shows Median Pfs of 11.1 Months VS 5.6 Months Compared to Alpelisib Plus Fulvestrant- SEC Filing

THOMSON REUTERS
·
Jun 02

Celcuity - FDA Grants Priority Review to Celcuity's Gedatolisib Nda; Pdufa Date July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 02

Celcuity - Announces Phase 3 Viktoria-1 Trial Results for Pik3CA Mt Cohort - SEC Filing

THOMSON REUTERS
·
Jun 02